annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
1:00 PM - 4:00 PM
PLENARY SESSION
Plenary Session including Science of Oncology Award and Lecture
Location: N Hall B1
CME credit: 3
Track(s): Special Session; General Oncology
Douglas W. Blayney, MD—Co-Chair
University of Michigan
Daniel F. Hayes, MD—Co-Chair
University of Michigan Medical Center
1:00 PM Frank McCormick, PhD—Science of Oncology Award Recipient
University of California, San Francisco Helen Diller Family Comprehensive Cancer
Center
Success and Failure on the Ras Pathway
1:45 PM Phase III trial of bevacizumab (BEV) in the primary treatment of advanced
epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian
tube cancer (FTC): A Gynecologic Oncology Group study. (Abstract #LBA1)
R. A. Burger, M. F. Brady, M. A. Bookman, J. L. Walker, H. D. Homesley, J. Fowler,
B. J. Monk, B. E. Greer, M. Boente, S. X. Liang
Discussion
2:00 PM Elisabeth A. Eisenhauer, MD (Abstract #LBA1)
NCIC Clinical Trials Group
2:15 PM Weekly paclitaxel combined with monthly carboplatin versus single-agent
therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in
advanced non-small cell lung cancer (NSCLC). (Abstract #2)
E. A. Quoix, J. Oster, V. Westeel, E. Pichon, G. Zalcman, L. Baudrin, A. Lavole,
J. Dauba, M. Lebitasy, B. J. Milleron, on behalf of IFCT
2:30 PM Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive
patients with non-small cell lung cancer (NSCLC). (Abstract #3)
Y. Bang, E. L. Kwak, A. T. Shaw, D. R. Camidge, A. J. Iafrate, R. G. Maki,
B. J. Solomon, S. I. Ou, R. Salgia, J. W. Clark
Discussion
2:45 PM Martin J. Edelman, MD (Abstracts #2–3)
University of Maryland Greenebaum Cancer Center
3:05 PM A phase III, randomized, double-blind, multicenter study comparing
monotherapy with ipilimumab or gp100 peptide vaccine and the combination
in patients with previously treated, unresectable stage III or IV melanoma.
(Abstract #4)
S. O’Day, F. S. Hodi, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen,
X. Zhu, M. J. Yellin, A. Hoos, W. J. Urba
Discussion
3:20 PM Vernon K. Sondak, MD (Abtract #4)
H. Lee Moffitt Cancer Center & Research Institute
Ipilimumab: The Light at the End of the Tunnel?
246